Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel application of Elabela polypeptide and medicine thereof

A technology of medicine and use, which is applied in the new use of Elabela polypeptide and its medicine field, can solve unseen problems, achieve the effects of less toxic and side effects, alleviate glomerular pathological damage, and ease the development

Pending Publication Date: 2020-04-07
GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no use of Elabela polypeptide in the treatment of chronic kidney injury related to hypertension

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of Elabela polypeptide and medicine thereof
  • Novel application of Elabela polypeptide and medicine thereof
  • Novel application of Elabela polypeptide and medicine thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment one, sustained-release tablet

[0032]

[0033]

[0034] Preparation:

[0035] Weigh the original Elabela peptide, gelatin, and lactose according to the prescription amount, pass through a 100-mesh sieve, mix well, add an appropriate amount of povidone K30 to make a soft material, granulate with a 24-mesh standard sieve, and dry at 50°C for 1.0h. 20-mesh sieve Whole grain; adding magnesium stearate, punching into tablets, that is.

Embodiment 2

[0036] Embodiment two, sustained-release tablet

[0037] Element Dosage Elabela peptide 0.1wt% gelatin 40.0wt% lactose 4.0wt% Magnesium stearate 2.0wt% Povidone K30 (3%) margin

[0038] The preparation method is as in Example 1.

Embodiment 3

[0039] Embodiment three, sustained-release tablet

[0040] Element Dosage Elabela peptide 1.5wt% gelatin 40.0wt% lactose 3.0wt% Magnesium stearate 2.0wt% Povidone K30 (3%) margin

[0041] The preparation method is as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Elabela polypeptide in preparation of a medicine or functional food for preventing and / or treating diseases related to chronic kidney injury and the medicinethereof. The diseases related to chronic kidney injury comprise (i) chronic renal insufficiency caused by hypertension; or ii) chronic renal insufficiency with hypertension. The Elabela polypeptide isstable in blood pressure reduction, can effectively relieve glomerular pathological injury of SD rats induced by deoxycorticosterone, reduce discharge of urine microalbumin, relieve development of renal fibrosis and reduce expression of inflammatory factors in kidney tissues, and has a remarkable effect on treatment of chronic kidney injury. Meanwhile, the Elabela polypeptide is an endogenous hormone synthesized by a human body and is expressed in kidney tissue, so that the toxic and side effects are smaller than those of the existing medicine for treating chronic kidney injury.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the new application of Elabela polypeptide and its medicine. Background technique [0002] Chronic renal insufficiency affects 8-16% of the world's population and has become a worldwide public health and health problem. Studies have shown that chronic renal insufficiency not only affects the urinary system, but is also closely related to cardiovascular and cerebrovascular diseases, hypertension, and diabetes. In high-income countries and middle-income countries, hypertension has become the second leading cause of chronic renal insufficiency. In my country, the incidence of hypertensive renal injury has also been increasing in recent years. Chronic renal insufficiency caused by hypertension has an insidious onset and atypical clinical symptoms at the initial stage. Early lifestyle improvement and drug intervention can reduce the occurrence of end-stage renal failu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P13/12A61P9/12A23L33/18
CPCA61K38/1709A61P13/12A61P9/12A23L33/18
Inventor 王蕾陈志达邬春莹
Owner GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com